{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:26Z","timestamp":1792782866090,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic treatment offers only modest survival benefits in previously treated metastatic gastroesophageal adenocarcinoma (GEA). Treatment monitoring using imaging-based response assessments are often delayed and imprecise, highlighting the need for biomarkers to guide early treatment decisions. We evaluated the value of circulating tumor DNA (ctDNA) for prognosis, patient selection, and on-treatment monitoring in patients with previously treated GEA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study aimed to investigate whether baseline ctDNA levels and early ctDNA changes assessed by ctDNA-RECIST were associated with survival outcomes in a randomized Phase 2 trial comparing trifluridine-tipiracil plus bevacizumab or trifluridine-tipiracil alone. Plasma samples were collected at baseline and during treatment (weeks 4 and 8). ctDNA was quantified by a tumor-agnostic methylation-specific digital droplet PCR (ddPCR) assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma samples were available in 86 patients out of a total of 103 patients included in the trial. Patients with the highest baseline ctDNA levels (top 20%, n\u2009=\u200918) had significantly shorter progression-free survival (PFS; median 1.8 vs. 4.6\u00a0months; HR 2.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) and overall survival (OS; median 5.5 vs. 9.9\u00a0months; HR 2.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) compared to those with lower levels. Early progression by ctDNA at four weeks (HR 2.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) and at eight weeks by radiological assessment (HR 2.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) were both associated with inferior OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ctDNA is a strong prognostic biomarker in refractory GEA. High baseline levels and early increases identify patients unlikely to benefit from treatment. Prospective validation is needed, but ctDNA monitoring may enable earlier therapeutic decision-making in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-026-01743-w","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:15:02Z","timestamp":1779520502000},"page":"798-807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma"],"prefix":"10.1007","volume":"29","author":[{"given":"Cecilie Riis","family":"Iden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"\u00d8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Mohammad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Coordt","family":"Elle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Nordsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenna","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Lindbjerg","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"B\u00e6ksgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Qvortrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-1250","authenticated-orcid":false,"given":"Morten","family":"Mau-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"3","key":"1743_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10294","key":"1743_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"10302","key":"1743_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"10","key":"1743_CR4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004.","journal-title":"Ann Oncol"},{"issue":"10","key":"1743_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"17","key":"1743_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.21037\/atm-20-1159","volume":"8","author":"A Hsu","year":"2020","unstructured":"Hsu A, Zayac AS, Eturi A, Almhanna K. Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020. Ann Transl Med. 2020;8(17):1109\u20131109.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1743_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10555-016-9632-2","volume":"35","author":"E ter Veer","year":"2016","unstructured":"ter Veer E, Haj Mohammad N, van Valkenhoef G, Ngai LL, Mali RMA, van Oijen MGH, et al. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Rev. 2016;35(3):439\u201356.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"1743_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437\u201348.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1743_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"1743_CR10","unstructured":"Moati E, Taly V, Garinet S, Didelot A, Taieb J, Laurent\u2010puig P, et al. Role of circulating tumor dna in gastrointestinal cancers: Current knowledge and perspectives. Vol. 13, Cancers. MDPI; 2021"},{"issue":"6","key":"1743_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5306\/wjco.v13.i6.473","volume":"13","author":"P Kirchweger","year":"2022","unstructured":"Kirchweger P, Wundsam HV, Rumpold H. Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies. World J Clin Oncol. 2022;13(6):473\u201384.","journal-title":"World J Clin Oncol"},{"key":"1743_CR12","doi-asserted-by":"crossref","unstructured":"\u00d8gaard N, Iden CR, Jensen S\u00d8, Mustafa SM, Aagaard E, Bramsen JB, et al. DNA methylation markers for sensitive detection of circulating tumor DNA in patients with gastroesophageal cancers. ESMO Gastrointestinal Oncology [Internet]. 2024 Dec;6:100104. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000657","DOI":"10.1016\/j.esmogo.2024.100104"},{"issue":"8","key":"1743_CR13","first-page":"1","volume":"51","author":"YW Kim","year":"2019","unstructured":"Kim YW, Kim YH, Song Y, Kim HS, Sim HW, Poojan S, et al. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer. Exp Mol Med. 2019;51(8):1\u201310.","journal-title":"Exp Mol Med"},{"issue":"4","key":"1743_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","volume":"32","author":"E Ococks","year":"2021","unstructured":"Ococks E, Frankell AM, Masque Soler N, Grehan N, Northrop A, Coles H, et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol. 2021;32(4):522\u201332.","journal-title":"Ann Oncol"},{"issue":"1","key":"1743_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41467-020-14310-3","volume":"11","author":"A Leal","year":"2020","unstructured":"Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11(1):525.","journal-title":"Nat Commun"},{"issue":"23","key":"1743_CR16","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019;25(23):7098\u2013112.","journal-title":"Clin Cancer Res"},{"key":"1743_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01556-9","author":"CR Iden","year":"2025","unstructured":"Iden CR, Mustafa SM, \u00d8gaard N, Henriksen T, Jensen S\u00d8, Ahlborn LB, et al. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer. 2025. https:\/\/doi.org\/10.1007\/s10120-024-01556-9.","journal-title":"Gastric Cancer"},{"key":"1743_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejca.2022.11.039","volume":"180","author":"AKM Jakobsen","year":"2023","unstructured":"Jakobsen AKM, Spindler KLG. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. Eur J Cancer. 2023;180:180\u20133.","journal-title":"Eur J Cancer"},{"key":"1743_CR19","doi-asserted-by":"crossref","unstructured":"Spindler KLG, Jakobsen A. Circulating tumor DNA: Response evaluation criteria in solid tumors\u2013can we RECIST? Focus on colorectal cancer. Vol. 15, Therapeutic Advances in Medical Oncology. SAGE Publications Inc.; 2023","DOI":"10.1177\/17588359231171580"},{"key":"1743_CR20","first-page":"70","volume":"1","author":"L Baeksgaard Jensen","year":"2024","unstructured":"Baeksgaard Jensen L, Yilmaz M, Nordsmark M, M\u00f6ller S, Elle IC, Ladekarl M, et al. TRIFLURIDINE\/TIPIRACIL (FTD\/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trial. EClinicalMedicine. 2024;1:70.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1743_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13148-019-0757-3","volume":"11","author":"S\u00d8 Jensen","year":"2019","unstructured":"Jensen S\u00d8, \u00d8gaard N, \u00d8rntoft MBW, Rasmussen MH, Bramsen JB, Kristensen H, et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer\u2014a clinical biomarker discovery and validation study. Clin Epigenetics. 2019;11(1):158.","journal-title":"Clin Epigenetics"},{"issue":"7","key":"1743_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/clinchem\/hvaa100","volume":"66","author":"S\u00d8 Jensen","year":"2020","unstructured":"Jensen S\u00d8, \u00d8gaard N, Nielsen HJ, Bramsen JB, Andersen CL. Enhanced performance of DNA methylation markers by simultaneous measurement of sense and antisense DNA strands after cytosine conversion. Clin Chem. 2020;66(7):925\u201333.","journal-title":"Clin Chem"},{"issue":"15","key":"1743_CR23","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306\u201314.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1743_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1756283X15585468","volume":"8","author":"H Ford","year":"2015","unstructured":"Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol. 2015;8(4):189\u2013205.","journal-title":"Therap Adv Gastroenterol"},{"issue":"11","key":"1743_CR25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1743_CR26","doi-asserted-by":"publisher","first-page":"17756","DOI":"10.18632\/oncotarget.24879","volume":"9","author":"C Vandeputte","year":"2018","unstructured":"Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, et al. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget. 2018;9(25):17756\u201369.","journal-title":"Oncotarget"},{"issue":"8","key":"1743_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41416-020-1002-8","volume":"123","author":"MR Openshaw","year":"2020","unstructured":"Openshaw MR, Mohamed AA, Ottolini B, Fernandez-Garcia D, Richards CJ, Page K, et al. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br J Cancer. 2020;123(8):1271\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"1743_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s43856-025-00867-x","volume":"5","author":"D Tougeron","year":"2025","unstructured":"Tougeron D, Louvet C, Desram\u00e9 J, Evesque L, Angelergues A, Carnot A, et al. Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. Communications Medicine. 2025;5(1):136.","journal-title":"Communications Medicine"},{"key":"1743_CR29","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Bajor DL, Lumish MA, Conces M, Mohamed A, Mahipal A, et al. Short interval circulating tumor DNA (ctDNA) kinetics as a predictor of tumor re-sponse in patients with gastrointestinal (GI) cancer receiving immune checkpoint inhibitor (ICI)-based treatment. 2025.","DOI":"10.1200\/JCO.2025.43.4_suppl.836"},{"issue":"23","key":"1743_CR30","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.3390\/cancers16233960","volume":"16","author":"S Tatalovic","year":"2024","unstructured":"Tatalovic S, Doleschal B, Kupferthaler A, Grundner S, Burghofer J, Webersinke G, et al. Circulating tumor DNA (ctDNA) dynamics predict early response to treatment in metastasized gastroesophageal cancer (mGEC) after 2 weeks of systemic treatment. Cancers. 2024;16(23):3960.","journal-title":"Cancers"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01743-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01743-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01743-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:49:10Z","timestamp":1782715750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01743-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01743-w","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures were conducted in accordance with institutional and national ethical standards and the Declaration of Helsinki. The study was approved by the Ethics Committee of the Capital Region Denmark. Informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}